NASDAQ:INBX Inhibrx Biosciences (INBX) Stock Price, News & Analysis $90.25 -0.25 (-0.28%) As of 10:28 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Inhibrx Biosciences Stock (NASDAQ:INBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inhibrx Biosciences alerts:Sign Up Key Stats Today's Range$87.73▼$90.7250-Day Range$85.26▼$126.7052-Week Range$28.16▼$155.29Volume14,281 shsAverage Volume311,220 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$197.50Consensus RatingModerate Buy Company Overview Inhibrx Biosciences, Inc. is a biotechnology company focused on discovering and developing engineered biologic medicines for serious diseases with limited treatment options. The company’s platform has been used to create multifunctional proteins and antibody-based therapies designed to address targets that may be difficult to treat with conventional drugs. Its leading program was INBRX-101, an engineered recombinant human alpha-1 antitrypsin therapy developed for patients with alpha-1 antitrypsin deficiency-associated lung disease. Inhibrx also advanced additional investigational therapies, including INBRX-109, an antibody-based treatment candidate studied in oncology. These products have been evaluated through clinical development programs rather than commercialized as approved medicines by the company. Inhibrx was founded in 2010 and was based in La Jolla, California. In 2024, Sanofi completed its acquisition of Inhibrx, gaining rights to the company’s principal programs, including INBRX-101. The company’s development activities and clinical programs have been directed primarily toward patients in the United States and other international markets through global research and clinical-trial efforts.AI Generated. May Contain Errors. Read More Inhibrx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreINBX MarketRank™: 3.591475409835 of 5 starsInhibrx Biosciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 254th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingInhibrx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInhibrx Biosciences has a consensus price target of $197.50, representing about 119.0% upside from its current price of $90.17.Amount of Analyst CoverageInhibrx Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Inhibrx Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inhibrx Biosciences are expected to grow in the coming year, from ($9.91) to ($9.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx Biosciences is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx Biosciences is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx Biosciences has a P/B Ratio of 163.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inhibrx Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.53% of the float of Inhibrx Biosciences has been sold short.Short Interest Ratio / Days to CoverInhibrx Biosciences has a short interest ratio ("days to cover") of 11.82, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibrx Biosciences has recently increased by 1.15%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibrx Biosciences does not currently pay a dividend.Dividend GrowthInhibrx Biosciences does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.15 News SentimentInhibrx Biosciences has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inhibrx Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Inhibrx Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership4.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Inhibrx Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $6,178,917.00 in company stock, which represents 0.4655% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Inhibrx Biosciences insiders have bought 3,665.06% more of their company's stock than they have sold. Specifically, they have bought $6,347,507.00 in company stock and sold $168,590.00 in company stock.Percentage Held by Insiders18.26% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx Biosciences' insider trading history. Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INBX Stock News HeadlinesAre Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?October 14 at 12:41 AM | finance.yahoo.comInhibrx Announces Participation in Upcoming Scientific ConferencesOctober 13 at 4:00 PM | prnewswire.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 16 at 1:00 AM | Banyan Hill Publishing (Ad)Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech SetupInhibrx Biosciences' CEO bought $3.6 million in shares after strong Phase 2 data, as insiders accumulate stock amid heavy short interest and an upcoming FDA decision on ozekibart.October 2, 2026 | marketbeat.comInhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp ReratingSeptember 29, 2026 | finance.yahoo.comInhibrx Biosciences (NASDAQ:INBX) CEO Acquires $453,420.00 in StockSeptember 29, 2026 | insidertrades.comInhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?September 24, 2026 | uk.finance.yahoo.comInhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?September 15, 2026 | fool.comSee More Headlines INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx Biosciences' stock was trading at $79.00 on January 1st, 2026. Since then, INBX stock has increased by 14.1% and is now trading at $90.17. How were Inhibrx Biosciences' earnings last quarter? Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.28) by $0.06. When did Inhibrx Biosciences IPO? Inhibrx Biosciences (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx Biosciences' major shareholders? Inhibrx Biosciences' top institutional shareholders include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Jon Faiz Kayyem, Douglas Forsyth, Global Investors Lp Viking, Kimberly Manhard and Kristiina Md Vuori. View institutional ownership trends. How do I buy shares of Inhibrx Biosciences? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibrx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include CRISPR Therapeutics (CRSP), CrowdStrike (CRWD), Plug Power (PLUG), Pfizer (PFE), Quantum Computing (QUBT), Corning (GLW) and Iovance Biotherapeutics (IOVA). Company Calendar Last Earnings8/13/2026Today10/16/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 11 days, INBX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INBX CIK2007919 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees110Year Founded2017Price Target and Rating Average Price Target for Inhibrx Biosciences$197.50 High Price Target$245.00 Low Price Target$150.00 Potential Upside/Downside+118.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($8.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.05 million Net MarginsN/A Pretax Margin-10,014.08% Return on Equity-563.90% Return on Assets-83.48% Debt Debt-to-Equity RatioN/A Current Ratio5.07 Quick Ratio5.07 Sales & Book Value Annual Sales$1.30 million Price / Sales1,021.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book164.07Miscellaneous Outstanding Shares14,720,000Free Float12,030,000Market Cap$1.33 billion OptionableOptionable Beta3.81 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:INBX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredMy next big call (under $1)Bitcoin is down. Fear is high. Most investors are sitting on their hands. That's exactly when my biggest winne...Crypto 101 Media | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
